Abstract: Disclosed are compositions and methods useful for targeting molecules to activated macrophages, such as tumor associated macrophages. The compositions and methods are based on peptide sequences, such as AMT peptides, that home to activated macrophages. The disclosed homing to activated macrophages is useful for delivering therapeutic and detectable agents to cells and tissues where immune system effects or inflammation are occurring.

Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.

Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the following formula (I): wherein X1 represents a nitrogen atom or CR9, R1 represents a hydrogen atom, a C1-C6 alkyl group, or a C1-C6 alkoxy group, R2 represents a halogen atom, R3 represents a hydrogen atom or a halogen atom, R4 represents a hydrogen atom or a halogen atom, and R5 represents a C1-C3 alkylsulfonyl group, a substituted C1-C6 alkyl group, a substituted C1-C6 haloalkyl group, a substituted C1-C6 alkoxy group, or a substituted C1-C6 alkylamino group, or a pharmacologically acceptable salt thereof.

Abstract: The present invention relates to a novel fused ring compound having urea structure that exhibits excellent NAMPT activating effect, and a method using the same for treating/preventing metabolic disorder, cardiovascular and kidney disease, mitochondrial disease, neurodegenerative disease, ocular disease, and muscle wasting disorder. The present invention provides a compound represented by following formula (I) or a pharmacologically acceptable salt: Formula (I) wherein A, B, R, R2 and R3 represent the same meanings as in the claims.

Abstract: Provided herein are compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.

Abstract: A print consumable may include a rotatable core, a roll of dispensable print substrate, and a radio-frequency identification (RFID) tag. The roll of the dispensable print substrate may be dispensably secured to the core. The RFID tag may be secured to the core and configured to rotate about a core axis. The RFID tag includes an RFID antenna coupled to an RFID chip. The RFID chip may include a print counter, a stock-keeping unit (SKU) code, and a consumable authentication code. A print system may include a housing, a holder to hold the print consumable, a print head, a transceiver, a trace antenna for reading an RFID tag of the print consumable, and a controller. The controller may be configured to receive a signal from the transceiver indicative of one or more of the print counter, the SKU code, and the consumable authentication code received from the RFID antenna.

Abstract: Various embodiments relate to compounds and methods useful for preventing or treating a cancer in a subject. The method may include administering to a subject a composition according to any of the embodiments described herein in an amount effective to inhibit metastatic activity or tumor growth in the subject.

Abstract: The present disclosure provides a wearable garment comprising (a) a sheath having a first end and a second, wherein the sheath defines a cavity in a wearable position, wherein the sheath has a first opening at the first end, and wherein the sheath comprises a first material, and (b) one or more relief zones coupled to the sheath, wherein the relief zones comprise a second material, wherein a pressure distribution of the second material is greater than a pressure distribution of the first material.

Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

Abstract: Example stent grafts and methods for placement thereof are provided. An example stent graft may include (a) a main body stent graft defining a lumen that has a first end and a second end, (b) a diaphragm coupled to the main body stent graft, where the diaphragm defines at least three openings and (c) at least three stent graft extensions each defining a lumen, where a first end of each of the three stent graft extensions is coupled to one of the three openings.

Abstract: Disclosed herein are methods of diagnosing and treating MYC-driven cancers by detecting a PVT1 splice variant in a biological sample from a subject.

Abstract: Embodiments of the methods and compositions provided herein relate to inducing hair growth in a subject. Some embodiments include screening for agents to modulate hair growth.

Abstract: This disclosure relates to cardiogenic mesoderm formation regulators and methods of use thereof, e.g., generating a multipotent cardiovascular progenitor cell by overexpressing Id1, Id2, Id3, Id4, Evx1, and/or Grrp1 in a stem cell.

Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.